GO
Loading...

Eli Lilly and Co

More

  • US STOCKS-Earnings, overseas data lift futures Thursday, 24 Jul 2014 | 8:09 AM ET

    *U.S. manufacturing data due; Europe, China upbeat. NEW YORK, July 24- U.S. stock index futures rose on Thursday, following a record close on the S&P 500 index, lifted by strong data overseas and better than forecast results from Facebook.

  • Lilly 2Q profit falls 39 percent Thursday, 24 Jul 2014 | 7:23 AM ET

    INDIANAPOLIS— Eli Lilly and Co. on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations. The Indianapolis- based company said earnings declined to $733.5 million, or 68 cents per share, from $1.21 billion, or $1.11 per share, in the same quarter a year earlier.

  • UPDATE 1-Lilly beats forecasts, helped by cost controls Thursday, 24 Jul 2014 | 7:06 AM ET

    July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but earnings beat forecasts, helped by cost controls. Although revenue fell 17 percent to $4.94 billion, it topped Wall Street expectations of $4.90 billion.

  • Lilly beats forecasts, helped by cost controls Thursday, 24 Jul 2014 | 6:48 AM ET

    July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but overall results beat forecasts, helped by cost controls. The U.S. drugmaker on Thursday said it earned $734 million, or 68 cents per share, in the second quarter.

  • Final Glance: Pharmaceuticals companies Tuesday, 22 Jul 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 76 or 1.0 percent, to $76.87. Bristol-Myers Squibb Co. rose$. 20 or. 4 percent, to $49.12. Hospira rose$. 31 or. 6 percent, to $50.78.

  • Midday Glance: Pharmaceuticals companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Baxter International Inc. rose$. 93 or 1.2 percent, to $77.04. Bristol-Myers Squibb Co. rose$. 41 or. 8 percent, to $49.33. Hospira rose$. 27 or. 5 percent, to $50.74.

  • Early Glance: Pharmaceuticals companies Monday, 21 Jul 2014 | 11:37 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $76.15. Bristol-Myers Squibb Co. fell$. 28 or. 6 percent, to $48.84. Hospira fell$. 06 or. 1 percent, to $50.09.

  • ZURICH, July 16- Roche's experimental drug crenezumab failed to delay a decline in thinking and memory skills in people with Alzheimer's disease, a result likely to bolster a growing belief that drugs need to be given in earlier stages of the disease to show a benefit.

  • *Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.

  • Roche Alzheimer's drug fails main goals in mid-stage study Wednesday, 16 Jul 2014 | 11:30 AM ET

    ZURICH, July 16- Roche said its experimental Alzheimer's drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients' decline.

  • *Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than injectable insulins such as Eli Lilly and Co's Humalog and Novo Nordisk's NovoLog.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk.

  • A three-judge panel of the 6th U.S. Circuit Court of Appeals in Cincinnati rejected claims in 67 of the cases. Among the defendants in the various cases were Eli Lilly& Co, which won regulatory approval for Darvon in 1957 and Darvocet in 1972, and generic drug makers such as Mylan Inc and Teva Pharmaceutical Industries Ltd..

  • *Sanofi hit may be limited as EU market smaller than U.S. LONDON, June 27- European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015..

  • *Novo Nordisk deputy CEO sees group growing 10 pct annually. COPENHAGEN, June 25- Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • Medtronic’s $43B Covidien deal: More to come? Monday, 16 Jun 2014 | 9:26 AM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.

  • Diabetes: The $54 billion battleground Friday, 13 Jun 2014 | 12:17 PM ET
    Daily implements of diabetes care.

    Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.